Tranexamic Acid

Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics

Brand Names


Austria: Cyklokapron; Belgium: Exacyl; Cyprus: Azeptil, Tranexamic Acid; Czech Republic: Exacyl; Denmark: Cyklokapron; Estonia: Cyklokapron; Finland: Caprilon, Cyklokapron; France: Exacyl; Germany: Cyklokapron; Hungary: Exacyl; Ireland: Cyklokapron; Italy: Tranex, Ugurol; Latvia: Cyklokapron; Luxembourg: Exacyl; Malta: Cyklokapron, Tranexamic Acid; Netherlands: Cyklokapron; Poland: Exacyl; Romania: Exacyl; Spain: Amchafibrin; Sweden: Cyklo-f, Cyklokapron, Cyklonova, Tranexamsyra, Tranon; UK: Cyklokapron, Tranexamic Acid.

North America

Canada: Cyklokapron, Tranexamic Acid; USA: Cyklokapron, Lysteda.

Latin America

Brazil: Hemoblock, Transamin.


Japan: Hemlon, Hexatron, Keisamine, Nicolda, Pletasmin, Ranobis, Rikavarin, Tracapmin, Tranexan, Transabon, Transamin, Trasamlon, Vanarin Top, Youxamine.

Drug combinations

Tranexamic Acid and Protein C Concentrate (Human)


Tranexamic Acid: C~8~H~15~NO~2~. Mw: 157.21. (1) Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans-; (2) trans-4-(Aminomethyl)cyclohexanecarboxylic acid. CAS-1197-18-8 (1967).

Pharmacologic Category

Antihemorrhagic Agents; Hemostatics. Antihemophilic Agent. (ATC-Code: B02AA02).

Mechanism of action

Forms reversible complex which displaces plasminogen from fibrin resulting in inhibition of fibrinolysis. Also inhibits proteolytic activity of plasmin.

Therapeutic use

Short-term use (2-8 days) in hemophilia patients during and following tooth extraction to reduce or prevent hemorrhage.

Pregnancy and lactiation implications

Use with caution in pregnancy and lactation.

Unlabeled use

Has been used as alternative to aminocaproic acid for subarachnoid hemorrhage.


Acquired defective color vision, active intravascular clotting, subarachnoid hemorrhage, concurrent factor IX complex or anti-inhibitor coagulant concentrates.

Warnings and precautions

Use with caution in cardiovascular disease, in cerebrovascular disease and in renal impairment. When used for subarachnoid hemorrhage, ischemic complications may occur. Use with caution in thromboembolic disease (may increase risk of thrombosis).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart